GMAB (GMAB) Stock Price & Analysis
GMAB (GMAB) rose 1.21% to USD 25.1 as of June 9, 2026 at 23:49 UTC, according to Nexqual real-time market data.
GMAB last closed at USD 24.8; the session ranged USD 24.71–25.17 on volume of 1,322,589 shares. Market capitalization is $15.41B, with a 52-week range of USD 20.23–35.43 (NMS). Source: Nexqual, June 9, 2026 at 23:49 UTC.
Key Statistics (as of June 9, 2026 at 23:49 UTC)
| Price | USD 25.1 |
|---|---|
| Change | ▲ 1.21% (up) |
| Previous Close | USD 24.8 |
| Open | USD 24.88 |
| Day Range | USD 24.71 – 25.17 |
| 52-Week Range | USD 20.23 – 35.43 |
| Volume | 1,322,589 shares |
| Market Cap | $15.41B |
| Exchange | NMS |
Technical Analysis (GMAB)
Nexqual's technical model rates GMAB "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:49 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42.07 (neutral) |
| vs SMA50 | Below (USD 26.85) |
| MACD | -0.61 (negative) |
Analyst Ratings (GMAB)
Wall Street analysts rate GMAB "Strong Buy" based on 11 analysts, with a mean price target of USD 36.82 (range USD 32–41.5), per Nexqual as of June 9, 2026 at 23:49 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 11 |
| Mean Target | USD 36.82 |
| High Target | USD 41.5 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 9 / 2 / 0 |
Earnings (GMAB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| Revenue Estimate | $6.95B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.13 vs est 0.19 ▼ miss |
| 2025-12-31 | USD 0.21 vs est 0.37 ▼ miss |
| 2025-09-30 | USD 0.65 vs est 0.45 ▲ beat |
| 2025-06-30 | USD 0.54 vs est 0.34 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financials & Fundamentals (GMAB)
| Total Revenue | $3.90B |
|---|---|
| Revenue Growth (YoY) | +25.30% |
| Gross Margin | +93.31% |
| Operating Margin | +25.11% |
| Profit Margin | +21.05% |
| ROE | +14.96% |
| Debt / Equity | 94.18 |
| Current Ratio | 2.18 |
| Total Cash | $1.52B |
| Total Debt | $5.35B |
| Free Cash Flow | $830.37M |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Financial Health Score (GMAB)
Nexqual rates GMAB's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:49 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 93%, operating 25% |
| Balance Sheet | Mixed — $1.52B cash vs $5.35B debt |
| Cash Flow | Mixed — FCF $830M, slim 3.5% margin |
| Efficiency | Mixed — ROE 15%, ROA 8.5% |
Ownership (GMAB)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +13.58% |
| Shares Outstanding | 613.93M |
| Float | 606.43M |
| Short % of Float | +1.67% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Leadership (GMAB)
GMAB is led by Jan G.J. van de Winkel (age 64), Co-Founder, President & CEO, per Nexqual as of June 9, 2026 at 23:49 UTC.
| Co-Founder, President & CEO | Jan G.J. van de Winkel (age 64) |
|---|---|
| Executive VP & CFO | Anthony Pagano (age 47) |
| Executive VP & Chief Strategy Officer | Martine J. van Vugt (age 54) |
| Senior Director, Head of Development Business Partnership & Strategy and Director | Martin Schultz (age 50) |
| VP, Head of Antibody Research Materials & Director | Mijke Zachariasse (age 52) |
Major Backers & Investors (GMAB)
Notable institutional backers of GMAB include Orbis Allan Gray Ltd, Alliancebernstein L.P., Paradigm Biocapital Advisors LP, according to Nexqual as of June 9, 2026 at 23:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Orbis Allan Gray Ltd | 2.07% |
| Alliancebernstein L.P. | 1.53% |
| Paradigm Biocapital Advisors LP | 1.28% |
| Arrowstreet Capital, Limited Partnership | 0.8% |
| Renaissance Technologies | 0.71% |
| Deep Track Capital, Lp | 0.59% |
| Harding Loevner LP | 0.52% |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 0.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 1.3% |
Source: Nexqual, June 9, 2026 at 23:49 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 884 | ▼ 0.82% |
| LEGN | Legend Biotech Corporation | USD 33.49 | ▲ 2.67% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| LKFT | Lakefront Biotherapeutics | USD 28.27 | ▲ 0.89% |
| ZLAB | Zai Lab Limited | USD 16.65 | ▲ 0.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:49 UTC. This page is informational and not investment advice.